Over 140 AAIC 2026 presentations used Alamar Biosciences' NULISA data, underscoring rapid adoption of its blood-based Alzheimer's biomarker platform
Executive summary: Alamar Biosciences announced that more than 140 scientific presentations at AAIC 2026 featured data from its NULISA platform, including emerging eMTBR-Tau and BD-pTau217 blood-based biomarker research. This widespread use signals strong validation of NULISA technology for Alzheimer’s diagnostics and highlights growing interest in blood-based biomarkers within the neurology research community.
Who is involved: Alamar Biosciences, researchers presenting at AAIC 2026, and the Alzheimer’s Association International Conference organizers.
Likely next: Alamar Biosciences will host a scientific workshop at AAIC 2026 to further present eMTBR-Tau and BD-pTau217 data for Alzheimer’s detection and staging.
Alamar Biosciences reported that its NULISA assay data appeared in more than 140 scientific presentations at the Alzheimer’s Association International Conference (AAIC) 2026. The presentations highlighted emerging blood-based biomarkers eMTBR-Tau and BD-pTau217 for Alzheimer’s disease detection and staging. This extensive conference uptake demonstrates strong scientific validation of the NULISA platform and positions the company for potential growth in the blood-based diagnostic market.
Timeline
- — AAIC 2026 逾 140 份学术报告均采用 Alamar Biosciences NULISA 数据，彰显阿尔茨海默病血液生物标志物分析领域的进展 (GlobeNewswire)
- — Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer’s Biomarker Profiling (GlobeNewswire)
Analysis — what this means
Likely next events
- Alamar Biosciences will host a scientific workshop at AAIC 2026 to present eMTBR-Tau and BD-pTau217 research data.
Sectors affected
- blood-based Alzheimer's biomarker diagnostics
- neurodegenerative disease assay market
Key entities
Sources
- AAIC 2026 逾 140 份学术报告均采用 Alamar Biosciences NULISA 数据，彰显阿尔茨海默病血液生物标志物分析领域的进展 — GlobeNewswire
- Alamar Biosciences NULISA Data Featured in More Than 140 Scientific Presentations at AAIC 2026, Highlighting Advances in Blood-Based Alzheimer’s Biomarker Profiling — GlobeNewswire
Related cases
- Eisai’s subcutaneous Leqembi data signal a user‑friendly alternative that could widen the Alzheimer’s drug market and boost partner BioArctic’s revenues
- Leqembi’s subcutaneous autoinjector shows comparable efficacy and safety to IV form, potentially widening patient access
- Alamar Biosciences’ NULISA platform gains validation as its Alzheimer’s biomarker data is slated for presentation in over 140 AAIC 2026 sessions